Nov 21, 2019 / 03:20PM GMT
Eun Kyung Yang - Jefferies LLC, Research Division - MD & Senior Equity Research Analyst
Good afternoon. This is in Eun Yang, biotech analyst with Jefferies based in New York. Our next presenting company is Ionis Pharmaceuticals. As you know, Ionis is a RNA-targeted therapeutics company with a number of pharma partnerships in place and most notable is SPINRAZA partnered with Biogen.
And presenting from Ionis is Brett Monia, who's the Chief Operating Officer, but he will assume the role of CEO in January 2020. So welcome here. Welcome to the Jefferies conference, and we'll hear from Brett.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, COO, Senior VP of Translational Medicine & Director
Thank you, Eun. And good afternoon, everybody. Thanks for coming. Very pleased here today to provide you an update on Ionis Pharmaceuticals, where we are today and where we believe we're going in the future.
So first, starting with the forward-looking statements. Please look at these statements. They're forward-looking. So Ionis Pharmaceuticals
Ionis Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 21, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers